Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Carfilzomib is a proteasome inhibitor that irreversibly binds to its target, resulting in sustained proteasomal inhibition with minimal off-target effects. As a single agent, carfilzomib has demonstrated durable antimyeloma activity with manageable toxicities, which has resulted in its approval in Argentina, Israel, Mexico and the USA for the treatment of patients with relapsed and refractory multiple myeloma. Data from ongoing Phase III studies that are evaluating carfilzomib in earlier lines of therapy may facilitate an expanded indication for this agent, as well as for regulatory approval in the EU. This article summarizes the chemistry, pharmacokinetics, pharmacodynamics and available clinical data for carfilzomib in the treatment of patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)2121-2136
Number of pages16
JournalFuture Oncology
Volume11
Issue number15
DOIs
StatePublished - Aug 1 2015

Fingerprint

Multiple Myeloma
Proteasome Inhibitors
Argentina
Israel
Therapeutics
Secondary Prevention
Mexico
Pharmacokinetics
carfilzomib

Keywords

  • carfilzomib
  • efficacy
  • multiple myeloma
  • proteasome inhibitor
  • relapsed and/or refractory
  • safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. / Stewart, Alexander Keith.

In: Future Oncology, Vol. 11, No. 15, 01.08.2015, p. 2121-2136.

Research output: Contribution to journalArticle

@article{93ac2772c2064efbb138bd20e586ee65,
title = "Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma",
abstract = "Carfilzomib is a proteasome inhibitor that irreversibly binds to its target, resulting in sustained proteasomal inhibition with minimal off-target effects. As a single agent, carfilzomib has demonstrated durable antimyeloma activity with manageable toxicities, which has resulted in its approval in Argentina, Israel, Mexico and the USA for the treatment of patients with relapsed and refractory multiple myeloma. Data from ongoing Phase III studies that are evaluating carfilzomib in earlier lines of therapy may facilitate an expanded indication for this agent, as well as for regulatory approval in the EU. This article summarizes the chemistry, pharmacokinetics, pharmacodynamics and available clinical data for carfilzomib in the treatment of patients with multiple myeloma.",
keywords = "carfilzomib, efficacy, multiple myeloma, proteasome inhibitor, relapsed and/or refractory, safety",
author = "Stewart, {Alexander Keith}",
year = "2015",
month = "8",
day = "1",
doi = "10.2217/fon.15.123",
language = "English (US)",
volume = "11",
pages = "2121--2136",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma

AU - Stewart, Alexander Keith

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Carfilzomib is a proteasome inhibitor that irreversibly binds to its target, resulting in sustained proteasomal inhibition with minimal off-target effects. As a single agent, carfilzomib has demonstrated durable antimyeloma activity with manageable toxicities, which has resulted in its approval in Argentina, Israel, Mexico and the USA for the treatment of patients with relapsed and refractory multiple myeloma. Data from ongoing Phase III studies that are evaluating carfilzomib in earlier lines of therapy may facilitate an expanded indication for this agent, as well as for regulatory approval in the EU. This article summarizes the chemistry, pharmacokinetics, pharmacodynamics and available clinical data for carfilzomib in the treatment of patients with multiple myeloma.

AB - Carfilzomib is a proteasome inhibitor that irreversibly binds to its target, resulting in sustained proteasomal inhibition with minimal off-target effects. As a single agent, carfilzomib has demonstrated durable antimyeloma activity with manageable toxicities, which has resulted in its approval in Argentina, Israel, Mexico and the USA for the treatment of patients with relapsed and refractory multiple myeloma. Data from ongoing Phase III studies that are evaluating carfilzomib in earlier lines of therapy may facilitate an expanded indication for this agent, as well as for regulatory approval in the EU. This article summarizes the chemistry, pharmacokinetics, pharmacodynamics and available clinical data for carfilzomib in the treatment of patients with multiple myeloma.

KW - carfilzomib

KW - efficacy

KW - multiple myeloma

KW - proteasome inhibitor

KW - relapsed and/or refractory

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84938535127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938535127&partnerID=8YFLogxK

U2 - 10.2217/fon.15.123

DO - 10.2217/fon.15.123

M3 - Article

C2 - 26125319

AN - SCOPUS:84938535127

VL - 11

SP - 2121

EP - 2136

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -